belantamab mafodotin
Ligand Summary
Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
ChEMBL: CHEMBL4298209
DrugCentral: 5405
LyCHI: belantamab mafodotin
Target Activities
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Kd | BINDING AGENT | |||||
Kd | BINDING AGENT | |||||
Kd | BINDING AGENT | |||||
Kd | BINDING AGENT | |||||